RAD001 Plus Bevacizumab in Metastatic Melanoma

All patients will begin treatment with the same doses of RAD001 and bevacizumab. Patients will receive 6 weeks of treatment, followed by re evaluation. Patients with objective response or stable disease will continue treatment until disease progression.

During the study, all patients will receive 10 mg of RAD001 orally daily and 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.

Fifty-five patients will be enrolled in this multi-centered study

Inclusion criteria

• Histologically confirmed melanoma.
• Unresectable stage IV disease, or recurrent disease with metastases.
• Measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST]) or measurable skin lesions.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
• Life expectancy >=12 weeks.
• Patients are allowed 0-2 prior treatment regimens containing chemotherapy and/or immunotherapy (interferon, interleukin 2).
• Women of childbearing potential must have a negative serum pregnancy test with 7 days before beginning treatment.
• Absolute neutrophil count (ANC) >=1500/µL, and platelets >=100,000/µL.
• Serum creatinine <=2.0 mg/dL.
• Serum bilirubin <=1.5 mg/dL institutional upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 × ULN or <5 × ULN in patients with documented liver metastases.

Exclusion criteria

• Previous treatment with bevacizumab or other anti-angiogenesis agents.
• Previous treatment with mTOR inhibitors.
• Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A are not allowed.
• Treatment with investigational agents within 4 weeks of study entry.
• Treatment with more than two previous chemotherapy regimens.
• Immunization with attenuated live vaccines within one week of study or anytime during study treatment period.
• Female patients who are pregnant or breastfeeding.
• Central nervous system (CNS) involvement by metastatic melanoma.
• CNS disease (e.g., seizures not controlled with standard medical therapy, history of stroke).
• Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:

• Severely impaired lung function.
• Uncontrolled diabetes as defined by fasting serum glucose >1.5 ULN,
• Any acute or chronic uncontrolled infection/disorder.
• Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
• Any acute or chronic uncontrolled infection/disorder.
• Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
• Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
• Acute myocardial infarction (MI) with the previous 6 months.
• Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, New York Heart Association [NYHA] Class II or greater congestive heart failure [CHF], serious cardiac arrhythmia requiring medication), or >= grade 2 vascular disease.
• Clinical history of hemoptysis or hematemesis.
• Clinical evidence or history of a bleeding diathesis or coagulopathy.
• Major surgical procedures, fine-needle aspirations, or core biopsies with 7 days of starting treatment.
• Patients with PEG tubes or G-tubes.
• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
• Proteinuria at screening as demonstrated by either

• Urine protein:creatinine (UPC) ratio >= 1.0 at screening OR
• Urine dipstick for proteinuria >= 2+ (patients discovered to have >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible).